Telix Pharmaceuticals Limited (ASX: TLX, Telix), an Australia-based biopharmaceutical company, announced on Monday that it has named Dr Darren Patti as its new group chief operating officer (COO).

Dr Patti joined the company in March 2021 to head its United States operations. He has served as the US chief operating officer and general manager for the Americas region over the past three years. He has served in various roles at Sofie Biosciences for a period of 15 years. He has most recently served as vice president of Operations heading the operationalisation of the Sofie-Lantheus PSMA-PET imaging program.

Dr Christian Behrenbruch, managing director and group CEO, said, 'Darren has been an exemplary leader in our Americas region and fundamental to the success of our commercial operations and vertical integration strategy. Darren's deep experience in radiopharmacy network management and operations, combined with an intricate understanding of the Telix business makes him the ideal leader for our global operations function as we expand into new commercial markets and bolster our manufacturing capabilities to support our therapeutic and imaging programs. I am looking forward to continuing to work closely with Darren in this new role as we prepare to bring additional diagnostic products to market and drive towards our next phase as a leader in therapeutic radiopharmaceuticals and precision medicine.'